Exhibit 99.1

                           INTERLEUKIN GENETICS, INC.

                                135 Beaver Street
                                Waltham, MA 02452

               LETTER TO COMMISSION PURSUANT TO TEMPORARY NOTE 3T

                                 March 27, 2002


Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C.  20549-0408

Ladies and Gentlemen:

Pursuant to Temporary Note 3T to Article 3 of Regulation S-X, Interleukin
Genetics, Inc. has obtained a letter of representation from Arthur Andersen LLP
("Andersen") stating that the December 31, 2001 audit was subject to their
quality control system for the U.S. accounting and auditing practice to provide
reasonable assurance that the engagement was conducted in compliance with
professional standards, that there was appropriate continuity of Andersen
personnel working on the audit and availability of national office consultation.
Availability of personnel at foreign affiliates of Andersen is not relevant to
this audit.


                                Very truly yours,

                                Interleukin Genetics, Inc.

                                /s/ Fenel M. Eloi

                                Fenel M. Eloi
                                Chief Operating Officer/ Chief Financial Officer